NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis

$51.29
+0.45 (+0.89 %)
(As of 06/24/2019 04:00 PM ET)
Today's Range
$50.61
Now: $51.29
$51.35
50-Day Range
$46.79
MA: $48.96
$52.40
52-Week Range
$41.23
Now: $51.29
$52.83
Volume1.85 million shs
Average Volume1.40 million shs
Market Capitalization$125.33 billion
P/E Ratio20.35
Dividend Yield2.18%
Beta0.58
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.7754 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,443,528,000
Market Cap$125.33 billion
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a special dividend on Thursday, August 9th. Shareholders of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S declared that its board has approved a share repurchase plan on Friday, February 2nd 2018, which allows the company to repurchase shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Friday, May, 3rd. The company reported $0.66 EPS for the quarter, topping the Zacks' consensus estimate of $0.62 by $0.04. The company earned $4.46 billion during the quarter, compared to analysts' expectations of $4.35 billion. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Novo Nordisk A/S.

What price target have analysts set for NVO?

16 brokers have issued twelve-month price objectives for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $355.00. On average, they expect Novo Nordisk A/S's share price to reach $126.97 in the next year. This suggests a possible upside of 147.6% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 9 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

News headlines about NVO stock have been trending neutral this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novo Nordisk A/S earned a news impact score of 0.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Novo Nordisk A/S.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,600,000 shares, a drop of 5.6% from the April 30th total of 2,753,900 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.1% of the company's stock are sold short. View Novo Nordisk A/S's Current Options Chain.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), Celgene (CELG), Johnson & Johnson (JNJ), Alibaba Group (BABA), Cisco Systems (CSCO), Netflix (NFLX), AbbVie (ABBV), General Electric (GE) and Intel (INTC).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.35%), Folketrygdfondet (0.21%), Sustainable Growth Advisers LP (0.14%), Everett Harris & Co. CA (0.13%), Northern Trust Corp (0.10%) and FMR LLC (0.09%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Folketrygdfondet, JPMorgan Chase & Co., Hutchinson Capital Management CA, Comerica Bank, Hikari Power Ltd and Autus Asset Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Jennison Associates LLC, Raymond James & Associates, Sphera Funds Management LTD., Clearbridge Investments LLC, Connor Clark & Lunn Investment Management Ltd., Richard C. Young & CO. LTD. and Sivik Global Healthcare LLC. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $51.29.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $125.33 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  303 (Thanks for Voting!)
Underperform Votes:  392 (Thanks for Voting!)
Total Votes:  695
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel